Cessation of Smoking Trial in the Emergency Department- interim results

Thursday, 24 November, 2022 - 13:20 to 14:50
Central square 3 (C3)

Abstract

Tobacco smoking is the leading cause of years of life-lost in the UK. Most current smokers want to quit, but need support. There have been no randomised controlled trials (RCTs) of smoking cessation interventions in the Emergency Department (ED) setting in the UK, which potentially provides a highly motivating opportunistic route to intervention. There has also been no RCTs of the use of e-cigarettes to aid smoking cessation in non-motivated quitters. The aim of this study is to definitively test real-world effectiveness of an ED based smoking cessation intervention with usual care.

Two-group, multi-centre, pragmatic, individually randomised, controlled trial (ClinicalTrial.gov: NCT04854616). We recruited people who smoked and were seeking medical attention from six EDs across the UK. They were randomised to either control (given written information about local stop smoking services) or intervention (a brief smoking cessation intervention, provision of an e-cigarette starter kit and training on its use and referral to stop smoking services). Both groups were followed up 1 month after randomisation and asked if they had smoked tobacco in the past 7 days. Qualitative observations of intervention delivery were undertaken as part of the process evaluation.

A total of 972 participants underwent randomisation. The ITT 1 month smoking point prevalence was XX% in the intervention group compared to XX% in the control group (data to be confirmed by September 2022). There was [no difference] in the rate of hospitalisation between intervention and control. Observations informed context of intervention delivery and enabled barriers to delivery to be addressed.

It is feasible to implement a smoking cessation intervention in ED with dedicated staff to deliver the intervention. Early finding suggest that (TBC following findings, expected September 2022). Participants will be followed up at 6 months to determine biochemically verified long term smoking status for the primary outcome.

Speakers

Presentation files

24 A4 1320 Ian Pope_v1.0.pdf579.19 KBDownload

Type

Tracks

Part of session